{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-025377","form_type":"8-K","ticker":"KNSA","cik":"0001730430","company_name":"Kiniksa Pharmaceuticals International, plc","filed_at":"2022-02-22T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.972645+00:00","generated_at":"2026-06-27T06:13:20.371702+00:00","sec_items":["1.01","2.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Kiniksa and Huadong Medicine $22M upfront Asia Pacific deal; ARCALYST FY2022 rev guidance $115-130M","bullets":["Upfront $22M from Huadong; up to $640M milestones + low-teens to low-twenties royalties on net sales for ARCALYST and mavrilimumab in Asia Pacific (ex-Japan).","ARCALYST net revenue $18.7M Q4 2021, $38.5M FY2021; collaboration achieved profitability in Q4.","FY2022 ARCALYST net revenue guidance $115-130M; cash $182.2M, no debt, funded into 2024.","No Phase 3 for mavrilimumab in giant cell arteritis; vixarelimab Phase 2b data in prurigo nodularis expected H2 2022.","Net loss $36.3M Q4 2021 vs $53.7M Q4 2020; full-year net loss $157.9M vs $161.4M in 2020."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-025377","json":"https://secwatch.observer/filing/0001104659-22-025377.json","markdown":"https://secwatch.observer/filing/0001104659-22-025377.md","text":"https://secwatch.observer/filing/0001104659-22-025377.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1730430/000110465922025377/0001104659-22-025377-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1730430/000110465922025377/tm227059d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T06:13:20.371702+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}